‹ ›
MYP_113871
← PREVIOUS NEXT → BACK
Basic Information
EKL1C
Anticancer
Anticancer ▸ Cytotoxic anticancer activity ▸ Cytotoxic
Antimicrobial
Antiviral
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV-2
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor
Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic
Venom / Toxin ▸ General toxin ▸ Cytotoxic
Standard
40 amino acids
C211H328N46O70S2
Standard
Sequence
NVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYGSGC
Physicochemical Analysis
4693.26 Da
4.39
-5.23
-5.48
-0.1309
-0.56
0.75
-0.03
15.32
87.75
0.1250
5960.00
5960.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1906.25
-12.90
66.0
67.0
164.0
329.0
5.0
40.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0041669 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
Chol
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2
wide type
0.049±0.007 μM
IC50
PaperA highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. Acta Pharm Sin B. 2022 Apr;12(4):1652-1661. doi: 10.1016/j.apsb.2021.07.026. PMID: 34367893 PMID35087243;34367893 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/35087243/
RECORD: Rec_0054574 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
Chol
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2
G476S
0.065±0.008 μM
IC50
PaperA highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. Acta Pharm Sin B. 2022 Apr;12(4):1652-1661. doi: 10.1016/j.apsb.2021.07.026. PMID: 34367893 PMID35087243;34367893 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/35087243/
RECORD: Rec_0058703 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
Chol
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2 Cytotoxic Anticancer
Caco-2 cells:CC50=13
PaperA highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. Acta Pharm Sin B. 2022 Apr;12(4):1652-1661. doi: 10.1016/j.apsb.2021.07.026. PMID: 34367893 PMID35087243;34367893 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/35087243/
RECORD: Rec_0058859 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
None
Chol
Chol
Bio-Activity Profile
Antiviral Fusion inhibition
G476S
0.065±0.008 μM
IC50
Mammalian: 1.4 h; Yeast: 3 min; E. coli: >10 h
PaperA highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. | Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q. | Acta Pharm Sin B. 2021 Aug 2. | DOI:10.1016/j.apsb.2021.07.026 | PMID:34367893 PMID34367893 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34367893/
RECORD: Rec_0065153 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
None
Chol
Chol
Bio-Activity Profile
Antiviral Fusion inhibition
D614G
0.104±0.01 μM
IC50
Mammalian: 1.4 h; Yeast: 3 min; E. coli: >10 h
PaperA highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. | Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q. | Acta Pharm Sin B. 2021 Aug 2. | DOI:10.1016/j.apsb.2021.07.026 | PMID:34367893 PMID34367893 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34367893/
FIRST PREV 1 2 3 4 5 ... 15 NEXT LAST
Showing 5 records on this page · Page 3 of 15